Empowered Funds LLC Buys New Stake in Amedisys, Inc. (NASDAQ:AMED)

Empowered Funds LLC bought a new position in Amedisys, Inc. (NASDAQ:AMED - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,500 shares of the health services provider's stock, valued at approximately $318,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Blue Trust Inc. increased its stake in Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock valued at $34,000 after buying an additional 124 shares during the period. HBW Advisory Services LLC purchased a new position in shares of Amedisys during the 4th quarter valued at $38,000. Versant Capital Management Inc increased its stake in shares of Amedisys by 68.5% in the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock worth $41,000 after acquiring an additional 183 shares during the last quarter. KBC Group NV purchased a new stake in shares of Amedisys during the third quarter worth $63,000. Finally, Signaturefd LLC boosted its position in Amedisys by 20.9% during the third quarter. Signaturefd LLC now owns 1,367 shares of the health services provider's stock valued at $132,000 after purchasing an additional 236 shares during the last quarter. Hedge funds and other institutional investors own 94.36% of the company's stock.

Amedisys Stock Down 0.7 %

Shares of Amedisys stock traded down $0.66 during midday trading on Friday, reaching $90.43. 592,415 shares of the company's stock traded hands, compared to its average volume of 300,824. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95. The company's 50 day simple moving average is $90.64 and its 200 day simple moving average is $93.48. The company has a market cap of $2.96 billion, a price-to-earnings ratio of 35.88, a price-to-earnings-growth ratio of 1.83 and a beta of 0.73.

Wall Street Analyst Weigh In

Separately, Stephens reaffirmed an "equal weight" rating and issued a $101.00 target price on shares of Amedisys in a research report on Wednesday, February 12th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $100.75.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.